KMPH
Closed
Kempharm Inc
4.97
+0.03 (+0.61%)
Last Update: 03 May 2023 16:30:00
Yesterday: 4.94
Day's Range: 4.85 - 5.14
Send
sign up or login to leave a comment!
When Written:
5.61
KemPharm Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of new therapies for the treatment of serious medical conditions. The company's proprietary drug discovery platform is based on its Ligand Activated Therapy (LAT) technology, which allows for the creation of prodrugs that are activated only when they reach their intended target.
KemPharm's pipeline includes several product candidates in various stages of development, including KP415, an extended-release prodrug of d-methylphenidate for the treatment of attention deficit hyperactivity disorder (ADHD), and KP879, an extended-release prodrug of benzhydrocodone for the treatment of pain.
The company was founded in 2006 and is headquartered in Celebration, Florida. It went public in 2015 and is traded on the NASDAQ stock exchange under the ticker symbol KMPH.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
KemPharm's pipeline includes several product candidates in various stages of development, including KP415, an extended-release prodrug of d-methylphenidate for the treatment of attention deficit hyperactivity disorder (ADHD), and KP879, an extended-release prodrug of benzhydrocodone for the treatment of pain.
The company was founded in 2006 and is headquartered in Celebration, Florida. It went public in 2015 and is traded on the NASDAQ stock exchange under the ticker symbol KMPH.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








